Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2019 09:26 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock

EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care...
August 09, 2019 09:22 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering

EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care...
November 12, 2014 07:03 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals Reports Third Quarter 2014 Financial Results and a Clinical/Business Update

Q3 Commercial Highlights: Initiation of the marketing campaign and commercialization effort for NovaBay's new product, i-Lid™ Cleanser, with medical sales representatives deployed in 10...
March 20, 2014 09:00 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants

EMERYVILLE, Calif., March 20, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial...
March 19, 2014 16:32 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants

EMERYVILLE, Calif., March 19, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial...
March 07, 2014 08:30 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals Reports Fourth Quarter 2013 and 2013 Year End Financial Results and Provides a Clinical/Business Update

Near-Term Clinical Catalysts: • Viral Conjunctivitis Trial Results to be Reported mid-2014 • Start of Second Phase 2 in UCBE...
March 06, 2014 15:22 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay CEO Comments on President Obama's 'Superbug' Budget Initiative and Reports by the CDC on Antibiotic Resistance

A recent journal article by NovaBay researchers describes the growing threat of resistance - and how the nation can fight it EMERYVILLE, Calif., March 6, 2014 (GLOBE NEWSWIRE) -- NovaBay®...
February 26, 2014 08:30 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals Grants Principle Business Enterprises Exclusive Marketing and Distribution Rights in the US for NeutroPhase(R), an Advanced Wound and Skin Cleanser

Recent In Vitro Study, Published in a Peer-Reviewed Journal, Demonstrated that NeutroPhase is Best Among Products Tested and Kills Bacteria Quickly New Minimally-Invasive Adjunctive Therapy...
February 17, 2014 09:30 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay's NeutroPhase(R) is Best in Class in Laboratory Study of 19 Top Commercial Wound Cleansers

The In Vitro Study, Published in the Peer-Reviewed Journal Advances in Skin & Wound Care, Showed that NeutroPhase Kills Bacteria Quickly Among the Products Tested, NeutroPhase Offered the Best...
February 07, 2014 08:30 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals to Present at the Annual Dialysis Conference in Atlanta

Nephrologist Allan Kavalich, MD, to Discuss Improvements in Infections Associated With Peritoneal Dialysis Catheters With Use of NeutroPhase - Pure 0.01% Hypochlorous Acid Solution EMERYVILLE,...